SQA
CNCR

Simon Quick Advisors’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Simon Quick Advisors’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,458
Closed -$34K – 517
2019
Q4 		$34K Buy
+1,458
New +$30.9K 0.01% 268

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Simon Quick Advisors's CNCR Position: Q1 2020 in Review

Simon Quick Advisors sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q1 2020, closing a stake of 1,458 shares — an estimated $34K sold.

Simon Quick Advisors first reported a position in CNCR in Q4 2019 and held it in 1 quarter. The position peaked at $34K in Q4 2019. 18 funds tracked by Wall St. Rank hold CNCR as of Q1 2020.

  • Simon Quick Advisors reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q1 2020 after selling out during the quarter.
  • Simon Quick Advisors sold 1,458 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q1 2020, an estimated $34K.
  • Simon Quick Advisors first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2019 and held it in 1 quarter.
  • Simon Quick Advisors's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $34K in Q4 2019.
  • 18 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q1 2020.

Based on Simon Quick Advisors's 13F filing for Q1 2020, filed 9 Apr 2020.